Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tumour Response.”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT06716853
What this trial is testing

A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma

Who this might be right for
Clear Cell RCC
Genenta Science 10
Very early researchStudy completedNCT01875666
What this trial is testing

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Who this might be right for
Breast Neoplasms
UNC Lineberger Comprehensive Cancer Center 26
Early research (Phase 1)Ended earlyNCT02317302
What this trial is testing

FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer

Who this might be right for
Cervical CancerUterine Cervical CancerUterine Cervical Neoplasms
Washington University School of Medicine 48
Testing effectiveness (Phase 2)UnknownNCT03951337
What this trial is testing

64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum)

Who this might be right for
Rectal Cancer
Institut Cancerologie de l'Ouest 70
Not applicableStudy completedNCT01871545
What this trial is testing

Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)

Who this might be right for
Hepatocellular CarcinomaHCC
Icahn School of Medicine at Mount Sinai 84
Testing effectiveness (Phase 2)Study completedNCT00588445
What this trial is testing

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Who this might be right for
Lung CancerNon-small Cell Lung CancerBronchioloalveolar Cancer
Memorial Sloan Kettering Cancer Center 65
Not applicableStudy completedNCT02276521
What this trial is testing

Evaluation of Long Term Immunity Following HPV Vaccination

Who this might be right for
Cervical CancerAnogenital Warts
Murdoch Childrens Research Institute 200
Not applicableStudy completedNCT05045963
What this trial is testing

Impact of Aminoglycosides in Hypotensive Septic Oncology Patients

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmSepticemia
M.D. Anderson Cancer Center 232
Not applicableUnknownNCT05832593
What this trial is testing

Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy.

Who this might be right for
Laryngeal Squamous Cell Carcinoma
Assiut University 52
Testing effectiveness (Phase 2)WithdrawnNCT04483414
What this trial is testing

68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer

Who this might be right for
Prostate CancerProstate Cancer MetastaticProstate Cancer Metastatic to Bone
Dana Mathews
Testing effectiveness (Phase 2)WithdrawnNCT02578121
What this trial is testing

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

Who this might be right for
Multiple Myeloma
University of Arkansas
Not applicableUnknownNCT05750693
What this trial is testing

PIK3CA in HER2+ BC and pCR Trial

Who this might be right for
HER2-positive Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 58
Not applicableStudy completedNCT04756921
What this trial is testing

18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

Who this might be right for
HER2-positive Breast Cancer
Biyun Wang, MD 30
Very early researchEnrolling By InvitationNCT06204614
What this trial is testing

Drug Screening Using IMD in Bladder Cancer

Who this might be right for
Muscle Invasive Bladder Urothelial Carcinoma
Brigham and Women's Hospital 18
Testing effectiveness (Phase 2)Study completedNCT00661375
What this trial is testing

BAY43-9006 Phase II Study for Renal Cell Carcinoma

Who this might be right for
Carcinoma, Renal Cell
Bayer 131
Early research (Phase 1)Ended earlyNCT02112162
What this trial is testing

Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery

Who this might be right for
Rectal Neoplasms
Washington University School of Medicine 2
Testing effectiveness (Phase 2)Study completedNCT04939662
What this trial is testing

Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects

Who this might be right for
Lung Cancer
Se-Hoon Lee 25
Not applicableUnknownNCT01863862
What this trial is testing

Organ Preservation in Elderly Patients With Rectal Cancer

Who this might be right for
Rectal Cancer
Maria Sklodowska-Curie National Research Institute of Oncology 90
Not applicableLooking for participantsNCT05704062
What this trial is testing

Quantitative MRI Assessment of Breast Cancer Therapy Response

Who this might be right for
Breast Cancer
Corewell Health East 135
Not applicableStudy completedNCT03650803
What this trial is testing

Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer

Who this might be right for
Breast Cancer
Case Comprehensive Cancer Center 14
Next Page